Abstract:Abstract 4815 Introduction: Acute myeloid leukemia (AML) is the most common type of adult leukemia for which cytosine arabinoside(Ara-C)-based chemotherapy is the main treatment. However, there is a significant difference in treatment response and survival, especially among large groups of patients with the same disease classification. Single nucleotide polymorphisms within the nucleotide excision repair pathway may alter the susceptibility of leukemia cells to chemotherapy. We investigated the role of six single nucleotide polymorphisms (ERCC5rs76871136, ERCC5rs77569659, ERCC5rs873601, XPCrs2228000, XPCrs2228001, and XPCrs1870134) within the nucleotide excision repair pathway on the outcome of patients with AML treated with cytosine arabinoside-based chemotherapy. Methods: One hundred fifty-one patients with AML in a Chinese population were enrolled in this study. Patients diagnosed with other cancers or other hematological malignancies were excluded in this study. This study was approved by the ethics committee of Southeast University in compliance with Chinese guidelines for blood donation, and informed consent for genetic analysis was obtained from all participants according to the Declaration of Helsinki. All patients received Ara-C-based standard induction chemotherapy regimens. Patients were divided into three groups, according to cytogenetic risk. Moreover, the evaluation standard of these patients were evaluated by age(£40 years, 40–60 years, and 360 years), WBC (>50 ′ 109/L vs. £50 ′ 109/L), hemoglobin level (>100 g/L vs. £100 g/L), and platelet count (>60 ′ 109/L vs. £60 ′ 109/L). Genotypes were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Deviations from the Hardy–Weinberg equilibrium for genotypes and haplotype frequencies as well as haplotype–trait associations were assessed with Pearson's c2 analysis using SHEsis. Once the expected number in any cell was less than five, demographic and clinical data across genotypes were compared using Pearson's c2analysis or Fisher's exact test. Significant genotypic differences among the different responders were calculated using Pearson's c2analysis. P <0.05 was considered statistically significant. We estimated the relative risk of responding to treatment with the genotypes as odds ratio(OR) and 95% confidence intervals(95%CI) using conditional logistic regression with adjustment for the effects of covariates. All statistical tests were two-sided and performed using SPSS 17.0. Results: Genotype frequencies for the polymorphisms were found to be in Hardy–Weinberg equilibrium. The results indicated that the distribution of three genotypes of XPCrs1870134 significantly differed among the cytogenetic risk groups (P = 0.04). The frequency of the CC genotype of XPCrs2228001 was significantly higher in male patients than in female patients (P = 0.03), whereas that of the CC genotype of XPCrs2228000 was significantly higher in patients with a hemoglobin level of 100 g/L or less compared with those who had a hemoglobin level greater than 100 g/L (P = 0.039).Moreover, patients carrying at least one variant allele (XPCrs2228001AA+CC) were more likely to respond better than those who did not carry a variant. However, no significant association was detected between polymorphisms in ERCC5 and treatment response. Conclusions: These findings suggest that XPC polymorphisms are important markers for the outcome of patients with AML in the Chinese population. Disclosures: No relevant conflicts of interest to declare.

Association of WT1 Rs16754 Polymorphism with Clinical Features and Prognosis in Patients with Acute Myeloid Leukemia

The Effect of WT1 Expression on the Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia

The Wilms Tumor-1 (WT1) Rs16754 Polymorphism is a Prognostic Factor in Acute Myeloid Leukemia (AML): a Meta-Analysis.

Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population

Immunorelated Gene Polymorphisms Associated with Acute Myeloid Leukemia

The Rs9909659g/A Polymorphisms of the Stat3 Gene Provide Prognostic Information in Acute Myeloid Leukemia

Genetic polymorphisms of IL-18 rs1946518 and IL-1β rs16944 are associated with prognosis and survival of acute myeloid leukemia

ATG 16 L 1 rs 2241880 polymorphism predicts unfavorable clinical outcomes for colorectal cancer patients in the Chinese population

Genetic variations in DNA excision repair pathway contribute to the chemosensitivity and prognosis of acute myeloid leukemia

A Genetic Polymorphism In Pre-Mir-27a Confers Clinical Outcome Of Non-Small Cell Lung Cancer In A Chinese Population

Study of Prognostic Variables in Acute Lymphoblastic Leukemia

[Relationship Between RAD51-g135C and XRCC3-C241T Polymorphisms and Prognosis of Inv (16)/ T(16;16) (Cbfbeta-Myh11) Acute Myeloid Leukemia].

The polymorphism of JAK2 rs56118985 may be a predictive marker of the treatment responses of acute myeloid leukemia patients

Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia

Polymorphisms in XPC Provide Prognostic Information in Acute Myeloid Leukemia

Polymorphisms in XRCC5, XRCC6, XRCC7 Genes Are Involved in DNA Double-Strand Breaks(dsbs) Repair Associated with the Risk of Acute Myeloid Leukemia(aml) in Chinese Population

KLK2 single-nucleotide polymorphism rs198977 is associated with increased susceptibility and hyperleukocytosis in AML

Functional Polymorphisms in the CD44 Gene and Acute Myeloid Leukemia Cancer Risk in a Chinese Population.

WT1 And DNMT3A Mutations in Prognostic Significance of Acute Myeloid Leukemia: A Meta-Analysis

Gene Polymorphisms of Molecules of the Cgas-Sting Signalling Pathway Are Associated with AML in Chinese Patients

High WT1 expression predicted induction chemotherapy failure in acute myeloid leukemia patients with non-favorable cytogenetic risk